Post by Hot Christian Stocks on Aug 15, 2013 22:42:06 GMT -5
Arch Therapeutics OTCQB:(ARTH) Company Overview and Description
Arch Therapeutics, Inc. (Arch) is a medical device company offering an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis*) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, “stasis and barrier applications.”
Physicians, industry and patients could benefit greatly from a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in a variety of consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools designed to resolve these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.
Arch’s products are currently progressing in preclinical development. The first product, AC5™, is designed to achieve hemostasis in minimally invasive (laparoscopic**) and open surgical procedures.
.jpg)
$ARTH Key Company Management
Terrence W. Norchi, MD; President, CEO, Director, Co-Founder
Terrence W. Norchi, MD is President and Chief Executive Officer of Arch Therapeutics, a company he co-founded in 2006 and led from an early stage of research to its current stage of development. Prior to Arch Therapeutics, Dr. Norchi was a portfolio manager, and pharmaceutical analyst, and head of the healthcare team at Putnam Investments. Previously, he was the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management. Prior to that he was s sell-side pharmaceutical analyst at Sanford C. Bernstein in New York City. He earned an M.B.A. from the MIT Sloan School of Management in 1996. Dr. Norchi completed internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as Chief Medical Resident. He earned an M.D. degree in 1990 from Northeast Ohio Medical University.
- See more at: www.archtherapeutics.com/company/leadership#sthash.ePoL2j0p.dpuf
$ARTH BIO Products
Hemostatic Agent: AC5™ for control over surgical bleeding.
AC5™ - more than just a better mousetrap
The hemostasis market is clearly in search of products that work better, faster, and more reliably. AC5™ is designed to do that. Arch believes its products will be significantly superior to what is currently available.
AC5™ is a synthetic peptide comprising naturally occurring amino acids. Evidence to-date supports that it is biocompatible. When squirted or sprayed onto a wound, AC5™ promptly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or, based on early data, clotting ability. Healing occurs normally.
The structural building process is called self-assembly, and it provides a new and improved approach to addressing “stasis and barrier applications.”
$ARTH Contact Info
Arch Therapeutics, Inc.
1 Broadway, 14th Floor
Cambridge, MA 02142, USA
Investor Relations
Tel: 1.855.340.ARTH (2784)
investors@archtherapeutics.com
Check out the $ARTH Website:
www.archtherapeutics.com
$ARTH SEC Filings
www.otcmarkets.com/stock/ARTH/filings
Headline News for $ARTH
finance.yahoo.com/q/h?s=ARTH+Headlines
$ARTH pipeline Milestones are awesome!!!
Investigate more about $ARTH @ www.otcmarkets.com/stock/ARTH/quote for more due diligence.
Arch Therapeutics, Inc. (Arch) is a medical device company offering an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis*) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, “stasis and barrier applications.”
Physicians, industry and patients could benefit greatly from a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in a variety of consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools designed to resolve these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.
Arch’s products are currently progressing in preclinical development. The first product, AC5™, is designed to achieve hemostasis in minimally invasive (laparoscopic**) and open surgical procedures.
$ARTH Key Company Management
Terrence W. Norchi, MD; President, CEO, Director, Co-Founder
Terrence W. Norchi, MD is President and Chief Executive Officer of Arch Therapeutics, a company he co-founded in 2006 and led from an early stage of research to its current stage of development. Prior to Arch Therapeutics, Dr. Norchi was a portfolio manager, and pharmaceutical analyst, and head of the healthcare team at Putnam Investments. Previously, he was the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management. Prior to that he was s sell-side pharmaceutical analyst at Sanford C. Bernstein in New York City. He earned an M.B.A. from the MIT Sloan School of Management in 1996. Dr. Norchi completed internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as Chief Medical Resident. He earned an M.D. degree in 1990 from Northeast Ohio Medical University.
- See more at: www.archtherapeutics.com/company/leadership#sthash.ePoL2j0p.dpuf
$ARTH BIO Products
Hemostatic Agent: AC5™ for control over surgical bleeding.
AC5™ - more than just a better mousetrap
The hemostasis market is clearly in search of products that work better, faster, and more reliably. AC5™ is designed to do that. Arch believes its products will be significantly superior to what is currently available.
AC5™ is a synthetic peptide comprising naturally occurring amino acids. Evidence to-date supports that it is biocompatible. When squirted or sprayed onto a wound, AC5™ promptly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or, based on early data, clotting ability. Healing occurs normally.
The structural building process is called self-assembly, and it provides a new and improved approach to addressing “stasis and barrier applications.”
$ARTH Contact Info
Arch Therapeutics, Inc.
1 Broadway, 14th Floor
Cambridge, MA 02142, USA
Investor Relations
Tel: 1.855.340.ARTH (2784)
investors@archtherapeutics.com
Check out the $ARTH Website:
www.archtherapeutics.com
$ARTH SEC Filings
www.otcmarkets.com/stock/ARTH/filings
Headline News for $ARTH
finance.yahoo.com/q/h?s=ARTH+Headlines
$ARTH pipeline Milestones are awesome!!!
Investigate more about $ARTH @ www.otcmarkets.com/stock/ARTH/quote for more due diligence.